The baseline time span for this database is (publication years)
1999-August 31, 2009 from the fourth bimonthly update (a 10-year + 8-month
period). The resulting database contained 22,696 (10 years) and 7,124 (2
years) papers; 56,958 authors; 110 nations; 2,445 journals; and
12,241institutions. See additional information below in the overview &
methodology sections.
Interviews, first-person essays, and profiles about
people in a wide variety of fields which pertain to
this special topic of Osteoporosis.
OVERVIEW
Osteoporosis is a skeletal disease characterized by loss of bone mineral
density. According to the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, osteoporosis is a threat to
approximately 44 million Americans—10 million with the disease
already and 34 million with a higher risk for developing it due to low bone
mass. 68% of these 44 million are women. The International Osteoporosis
Foundation estimates that there are 75 million people in Europe, the United
States, and Japan with osteoporosis.
In November 2002, we analyzed the literature for
osteoporosis from 1992-2002. This month, ScienceWatch.com
analyzes the literature on osteoporosis over the past decade and over
the past two years. The initial data pool was created using the search
term "osteoporosis" in titles, abstracts, and keywords of original
articles, reviews, and proceedings papers published between January 1,
1999 and August 31, 2009. To make the paper lists more targeted to
research specifically dealing with osteoporosis, we restricted the
search further with the same keywords, but only in the titles.
Large clinical trials for the risk assessment and/or treatment of
osteoporosis dominate the top papers over the past decade, including the
Framingham Osteoporosis Study, EPOS, and the US PSTF studies, which
examined risk assessment, and the MORE and TROPOS trials, which evaluated
treatments. Other issues under scrutiny include the prevalence of vitamin D
inadequacy in postmenopausal women receiving osteoporosis treatment, the
incidence of osteoporosis in men undergoing androgen deprivation therapy
for prostate cancer, the effects of treatment compliance on fractures, and
the predictive value of bone mineral density testing.
In the past two years, papers receiving citation attention cover such
topics as using parathyroid hormone to treat osteoporosis,
cost-effectiveness studies, genome-wide association studies, fracture risk
assessment guidelines, therapy compliance, and the specific problems
associated with osteoporosis in patients who also have chronic obstructive
pulmonary disease.
Methodology: The baseline time span for
this database is (publication years) 1999-August 31, 2009 from the
fourth bimonthly update (a 10-year + 8-month period). The resulting
database contained 22,696 (10 years) and 7,124 (2 years) papers; 56,958
authors; 110 nations; 2,445 journals; and 12,241institutions. See
additional information below in the overview & methodology sections.
Rankings: Once the database was in place, it was used to
generate list of authors, journals, institutions, and nations. Rankings for
author, journal, institution, and country are listed in three ways:
according to total cites, total papers, and total cites/paper*. The paper
thresholds and corresponding percentages used to determine scientist,
institution, country, and journal rankings according to total cites/paper,
and total papers respectively are as follows:
Entity
Authors
Institutions
Nations
Journals
Thresholds
16
74
17
5
Percentage:
1%
1%
50%
50%
*Unless otherwise specified, all rankings have a
5 paper threshold for all measures.
SPECIAL TOPIC KEYWORDS: OSTEOPOROSIS,
FRACTURE, HIP, JAW, RALOXIFENE, MORE STUDY,
POSTMENOPAUSAL WOMEN, BONE MINERAL DENSITY, SPINE,
RISEDRONATE, VITAMIN D, PREVENTION, DIAGNOSIS, RISK
ASSESSMENT, ALENDRONATE, MEN, GLUCOCORTICOID-INDUCED
OSTEOPOROSIS, RHEUMATOID ARTHRITIS, STRONTIUM
RANELATE, TROPOS STUDY, FRAMINGHAM OSTEOPOROSIS
STUDY, ANDROGEN DEPRIVATION THERAPY, PROSTATE
CANCER, OSTEOPROTEGERIN, OSTEOCLASTS, TREATMENT
COMPLIANCE, EPOS STUDY, SCREENING, PARATHYROID
HORMONE, GENOME-WIDE ASSOCIATION STUDY,
OSTEONECROSIS, ORAL BISPHOSPHONATES, PRACTICE
GUIDELINES, COST EFFECTIVENESS, ARTERIAL STIFFNESS,
CHRONIC OBSTRUCTIVE PULMONARY DISEASE, DUBBO
OSTEOPOROSIS EPIDEMIOLOGY STUDY, ENDOGENOUS SEX
HORMONES, CATHEPSIN K INHIBITORS, ZOLEDRONIC ACID,
DIABETES MELLITUS.